Multi-drug resistant tuberculosis (MDR-TB) in Ramnicul Valcear, Romania; drug treatment, resistance testing and adverse drug reactions Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006
Strategies against multidrug-resistant tuberculosis Source: Eur Respir J 2002; 20: 66S-77S Year: 2002
Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005
Frequency of side effects among patients with drug resistant tuberculosis (DR-TB) by resistance pattern in a high burden country. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Extensively drug resistant tuberculosis (XDR TB) in a high income country: a report of four unrelated cases Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007
The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis Source: Eur Respir J 2012; 39: 626-634 Year: 2012
Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009
Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003
Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay Source: Eur Respir J 2013; 41: 1163-1171 Year: 2013
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Outcome of multidrug resistant tuberculosis (MDR-TB) treatment with possible influencing factors Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011
The problem of one drug resistance in tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 858s Year: 2006
New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005
Recent transmission of drug resistant M. tuberculosis in Latvia Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Is it possible to achieve treatment success, recommended by WHO in country with high level of multidrug resistant TB? Source: Eur Respir J 2001; 18: Suppl. 33, 338s Year: 2001
MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009